Preoperative serum placenta growth factor level is a prognostic biomarker in colorectal cancer

Diseases of the Colon and Rectum

Volumn 52, Issue 9, 2009, Pages 1630-1636

  Wei, Shu Chen ^a   Liang, Jin Tung ^a   Tsao, Po Nien ^a   Hsieh, Fon Jou ^a   Yu, Sen Chang ^b   Wong, Jau Min ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

Author keywords

Carcinoembryonic antigen; Colorectal cancer; Placenta growth factor; Serum; SFlt 1; Vascular endothelial growth factor

Indexed keywords

BIOLOGICAL MARKER; CARCINOEMBRYONIC ANTIGEN; PLACENTAL GROWTH FACTOR; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; FLT1 PROTEIN, HUMAN; PLACENTA PROTEIN; PRODUCT PLACENTA GROWTH FACTOR; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ADULT; AGED; ANGIOGENESIS; ARTICLE; CANCER GROWTH; CANCER PATIENT; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PREOPERATIVE PERIOD; PROGNOSIS; PROTEIN BLOOD LEVEL; RECURRENCE RISK; SENSITIVITY AND SPECIFICITY; UPREGULATION; BLOOD; CASE CONTROL STUDY; COHORT ANALYSIS; COLON TUMOR; MIDDLE AGED; MORTALITY; PREDICTION AND FORECASTING; RECTUM TUMOR;

ADULT; AGED; AGED, 80 AND OVER; CARCINOEMBRYONIC ANTIGEN; CASE-CONTROL STUDIES; COHORT STUDIES; COLONIC NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PREGNANCY PROTEINS; PROGNOSIS; RECTAL NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 70249090040     PISSN: 00123706     EISSN: 15300358     Source Type: Journal    
DOI: 10.1007/DCR.0b013e3181afbdaf     Document Type: Article

References (30)

1. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004. CA Cancer J Clin 2004;54:8-29.
2. Wei SC, Tsao PN, Yu SC, et al. Placenta growth factor expression is correlated with survival of patients with colorectal cancer. Gut 2005;54:666-672
3. Stoeltzing O, Liu W, Reinmuth N, et al. Angiogenesis and antiangiogenic therapy of colon cancer liver metastasis. Ann Surg Oncol 2003;10:722-733
4. Takebayashi Y, Aklyama S, Yamada K, Akiba S, Aikou T. Angiogenesis as an unfavorable prognostic factor in human colorectal carcinoma. Cancer 1996;78:226-231
5. Vermeulen PB, Van den Eynden GG, Huget P, et al. Prospective study of intratumoral microvessel density, p53 expression and survival in colorectal cancer. Br J Cancer 1999;79:316-322
6. Lee JC, Chow NH, Wang ST, Huang SM. Prognostic value of vascular endothelial growth factor expression in colorectal cancer patients. Eur J Cancer 2000;36:748-753
7. Shiraishi A, Ishiwata T, Shoji T, Asano G. Expression of PCNA, basic fibroblast growth factor, FGF-receptor and vascular growth factor in adenomas and carcinomas of human colon. Acta Histochem Cytochem 1995;28:21-29
8. Wong MP, Cheung N, Yuen ST, Leung SY, Chung LP. Vascular endothelial growth factor is up-regulated in the early pre-malignant stage of colorectal tumour progression. Int J Cancer 1999; 81:845-850
9. Takahashi Y, Kitadai Y, Bucana CD, Cleary KR, Ellis LM. Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res 1995;55:3964-3968
10. Takahashi Y, Bucana CD, Cleary KR, Ellis LM. p53, vessel count, and vascular endothelial growth factor expression in human colon cancer. Int J Cancer 1998;79:34-38
11. Landriscina M, Cassano A, Ratto C, et al. Quantitative analysis of basic fibroblast growth factor and vascular endothelial growth factor in human colorectal cancer. Br J Cancer 1998;78:765-770
12. Khorana AA, Ryan CK, Cox C, Eberly S, Sahasrabudhe DM. Vascular endothelial growth factor, CD68, and epidermal growth factor receptor expression and survival in patients with Stage II and Stage III colon carcinoma: a role for the host response in prognosis. Cancer 2003;97:960-968
13. Andre T, Kotelevets L, Vaillant JC, et al. Vegf, Vegf-B, Vegf-C and their receptors KDR, FLT-1 and FLT-4 during the neoplastic progression of human colonic mucosa. Int J Cancer 2000;86: 174-181
14. Maglione D, Guerriero V, Viglietto G, Delli-Bovi P, Persico MG. Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor. Proc Natl Acad Sci USA 1991;88:9267-9271
15. Hauser S, Weich HA. A heparin-binding form of placenta growth factor (PlGF-2) is expressed in human umbilical vein endothelial cells and in placenta. Growth Factors 1993;9: 259-268
16. Cao Y, Linden P, Shima D, Browne F, Folkman J. In vivo angiogenic activity and hypoxia induction of heterodimers of placenta growth factor/vascular endothelial growth factor. J Clin Invest 1996;98:2507-2511
17. Kendall RL, Thomas KA. Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc Natl Acad Sci USA 1993;90:10705-10709
18. Chen CN, Hsieh FJ, Cheng YM, et al. The significance of placenta growth factor in angiogenesis and clinical outcome of human gastric cancer. Cancer Lett 2004;213:73-82.
19. Parr C, Watkins G, Boulton M, Cai J, Jiang WG. Placenta growth factor is over-expressed and has prognostic value in human breast cancer. Eur J Cancer 2005;41:2819-2827
20. Zhang L, Chen J, Ke Y, Mansel RE, Jiang WG. Expression of Placenta growth factor (PlGF) in non-small cell lung cancer (NSCLC) and the clinical and prognostic significance. World J Surg Oncol 2005;3:68.
21. Matsumoto K, Suzuki K, Koike H, et al. Prognostic significance of plasma placental growth factor levels in renal cell cancer: an association with clinical characteristics and vascular endothelial growth factor levels. Anticancer Res 2003;23:4953-4958
22. Tsao PN, Chan FT, Wei SC, et al. Soluble vascular endothelial growth factor receptor-1 protects mice in sepsis. Crit Care Med 2007;35:1955-1960.
23. Goldman CK, Kendall RL, Cabrera G, et al. Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate. Proc Natl Acad Sci USA 1998;95:8795-8800
24. Caine GJ, Blann AD, Stonelake PS, Ryan P, Lip GY. Plasma angiopoietin-1, angiopoietin-2 and Tie-2 in breast and prostate cancer: a comparison with VEGF and Flt-1. Eur J Clin Invest 2003;33:883-890
25. Werther K, Christensen IJ, Brunner N, Nielsen HJ. Soluble vascular endothelial growth factor levels in patients with primary colorectal carcinoma. The Danish RANX05 Colorectal Cancer Study Group. Eur J Surg Oncol 2000;26:657-662
26. De Vita F, Orditura M, Lieto E, et al. Elevated perioperative serum vascular endothelial growth factor levels in patients with colon carcinoma. Cancer 2004;100:270-278 (Pubitemid 38063634)
27. Karayiannakis AJ, Syrigos KN, Zbar A, et al. Clinical significance of preoperative serum vascular endothelial growth factor levels in patients with colorectal cancer and the effect of tumor surgery. Surgery 2002;131:548-555
28. Chin KF, Greenman J, Gardiner E, Kumar H, Topping K, Monson J. Pre-operative serum vascular endothelial growth factor can select patients for adjuvant treatment after curative resection in colorectal cancer. Br J Cancer 2000;83:1425-1431
29. Roumen RM, Slooter GD, Croiset van Uchelen FA, Huib LV. Preoperative serum vascular endothelial growth factor is not a marker for subsequent recurrence during long-term follow-up of colorectal cancer patients. Dis Colon Rectum 2005;48:1070-1075
30. Gonzalez FJ, Quesada AR, Sevilla I, et al. Prognostic value of serum angiogenic activity in colorectal cancer patients. J Cell Mol Med 2007;11:120-128